Polyrizon Regains Compliance with Nasdaq Listing Requirements
Rhea-AI Summary
Polyrizon (Nasdaq: PLRZ), a biotechnology company focused on intranasal product development, has successfully regained compliance with all Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel's Hearings Advisor on August 13, 2025, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The confirmation satisfies all previously outlined conditions by the Nasdaq Hearings Panel in their July 9, 2025 decision. As a result, Polyrizon will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol "PLRZ".
Positive
- Company has regained full compliance with Nasdaq listing requirements
- Maintained listing on Nasdaq Capital Market, avoiding potential delisting
Negative
- Previous non-compliance with Nasdaq minimum bid price requirements indicates historical stock price weakness
News Market Reaction
On the day this news was published, PLRZ gained 10.89%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.0% during that session. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $718K to the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the “Hearings Advisor”) of the Office of the General Counsel of the Nasdaq Hearings Panel (the “Nasdaq Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements.
In a letter dated August 13, 2025, the Hearings Advisor informed the Company that it has demonstrated compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) and satisfied the conditions of the Nasdaq Hearings Panel’s decision dated July 9, 2025.
This confirmation satisfies all conditions previously outlined by the Nasdaq Hearings Panel, and Polyrizon will continue to trade on the Nasdaq Capital Market under the ticker symbol “PLRZ.”
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
Has Polyrizon (PLRZ) regained Nasdaq compliance in 2025?
What was the specific Nasdaq requirement Polyrizon (PLRZ) needed to meet?
Will Polyrizon (PLRZ) continue trading on Nasdaq?
When did the Nasdaq Hearings Panel make their initial decision regarding Polyrizon?
